Basic Information
| Clone | Minretumomab Biosimilar |
|---|
| Molecular Weight | 150 kDa |
|---|
| Endotoxin | <1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay |
|---|
| Sterility | 0.2 μm filtration |
|---|
| Aggregation | <5% Determined by SECP |
|---|
| Purity | >95% Determined by SDS-PAGE |
|---|
Product Information
| Production | Purified from cell culture supernatant in an animal-free facility |
|---|
| Purification | Protein A or G purification |
|---|
| Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
|---|
Target Background
Minretumomab Biosimilar uses the same protein sequences as the therapeutic antibody minretumomab.Minretumomab is a mouse monoclonal antibody that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric and humanized minretumomab, as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.
Immunogen Information
| Isotype | Human IgG1 kappa |
|---|
| Immunogen | Human TAG-72 |
|---|
| RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody |
|---|
| Recommended Dilution Buffer | 1×PBS pH 7.0 |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
